Structural bases of protein kinase CK2 inhibition

Cellular and Molecular Life Sciences

Volumn 66, Issue 11-12, 2009, Pages 1868-1889

  Battistutta, R ^a  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

ATP binding site; Cancer; CK2; CK2 pharmacophore; Conserved water molecules; Inhibitors; Positive electrostatic area; Protein kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASEIN KINASE II; PROTEIN KINASE INHIBITOR;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; ENZYME ACTIVE SITE; HUMAN; PROTEIN BINDING; PROTEIN CONFORMATION; REVIEW; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CASEIN KINASE II; CATALYTIC DOMAIN; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS;

EID: 70349321218     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-009-9155-x     Document Type: Review

References (129)

1. Cohen, P. (1999) The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 3, 459-465.
2. Cohen, P. (2000) The regulation of protein function by multisite phosphorylation-a 25 year update. Trends Biochem. Sci. 25, 596-601.
3. Pinna, L. A. and Ruzzene, M. (1996) How do protein kinases recognize their substrates? Biochim. Biophys. Acta 1314, 191-225.
4. Ubersax, J. A. and Ferrell, J. E., Jr. (2007) Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 8, 530-541.
5. Knight, Z. A. and Shokat, K. M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
6. Goel, S., Mani, S. and Perez-Soler, R. (2002) Tyrosine kinase inhibitors: a clinical perspective. Curr. Oncol. Rep. 4, 9-19.
7. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
8. Hopkins, A. L. and Groom, C. R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727-730.
9. Cohen, P. (2002) Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315.
10. Levitzki, A. (2003) Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36, 462-469.
11. Cheng, Y. and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
12. Melnikova, I. and Golden, J. (2004) Targeting protein kinases. Nat. Rev. Drug Discov. 3, 993-4.
13. Fabian, M. A., Biggs, W. H., 3rd, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
14. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T. et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132.
15. Druker, B. J. (2004) Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30.
16. Druker, B. J. (2004) Imatinib: paradigm or anomaly? Cell Cycle 3, 833-835.
17. Pinna, L. A. and Cohen, P. T. W. (2005) Targeted theraphy with imatinib: an exception or a rule? In: Handbook of Experimental Pharmacology, pp. 361-390, Pinna, L. A. and Cohen, P. T. W. (eds.), Springer, Berlin.
18. Imming, P., Sinning, C. and Meyer, A. (2006) Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821-834.
19. Bogoyevitch, M. A., Barr, R. K. and Ketterman, A. J. (2005) Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochim. Biophys. Acta 1754, 79-99.
20. Bogoyevitch, M. A. and Fairlie, D. P. (2007) A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12, 622-633.
21. Parang, K. and Cole, P. A. (2002) Designing bisubstrate analog inhibitors for protein kinases. Pharmacol. Ther. 93, 145-157.
22. Parang, K., Till, J. H., Ablooglu, A. J., Kohanski, R. A., Hubbard, S. R. and Cole, P. A. (2001) Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol. 8, 37-41.
23. Shen, K., Hines, A. C., Schwarzer, D., Pickin, K. A. and Cole, P. A. (2005) Protein kinase structure and function analysis with chemical tools. Biochim. Biophys. Acta 1754, 65-78.
24. Pinna, L. A. and Cohen, P. T. W. (2005) New design strategies for ligands that target protein kinase-mediated protein-protein interactions. In: Handbook of Experimental Pharmacology, pp. 11-46, Pinna, L. A. and Cohen, P. T. W. (eds.), Springer, Berlin.
25. Burnett, G. and Kennedy, E. P. (1954) The enzymatic phosphorylation of proteins. J. Biol. Chem. 211, 969-980.
26. Pinna, L. A. (2002) Protein kinase CK2: a challenge to canons. J. Cell Sci. 115, 3873-8.
27. Meggio, F. and Pinna, L. A. (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17, 349-368.
28. Chardot, T., Shen, H. and Meunier, J. C. (1995) Dual specificity of casein kinase II from the yeast Yarrowia lipolytica. C. R. Acad. Sci. III 318, 937-942.
29. Marin, O., Meggio, F., Sarno, S., Cesaro, L., Pagano, M. A. and Pinna, L. A. (1999) Tyrosine versus serine/threonine phosphorylation by protein kinase casein kinase-2. A study with peptide substrates derived from immunophilin Fpr3. J. Biol. Chem. 274, 29260-29265.
30. Donella-Deana, A., Cesaro, L., Sarno, S., Brunati, A. M., Ruzzene, M. and Pinna, L. A. (2001) Autocatalytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182. Biochem. J. 357, 563-567.
31. Vilk, G., Weber, J. E., Turowec, J. P., Duncan, J. S., Wu, C., Derksen, D. R., Zien, P., Sarno, S., Donella-Deana, A., Lajoie, G. et al. (2008) Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells. Cell. Signal. 20, 1942-1951.
32. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275-282.
33. Johnson, L. N., Noble, M. E. and Owen, D. J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158.
34. Pinna, L. A. (1994) A historical view of protein kinase CK2. Cell. Mol. Biol. Res. 40, 383-90.
35. Litchfield, D. W. (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1-15.
36. Pinna, L. A. (2003) The raison d'être of constitutively active protein kinases: the lesson of CK2. Acc. Chem. Res. 36, 378-384.
37. Arrigoni, G., Pagano, M. A., Sarno, S., Cesaro, L., James, P. and Pinna, L. A. (2008) Mass spectrometry analysis of a protein kinase CK2beta subunit interactome isolated from mouse brain by affinity chromatography. J. Proteome Res. 7, 990-1000.
38. Bibby, A. C. and Litchfield, D. W. (2005) The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int. J. Biol. Sci. 1, 67-79.
39. Bolanos-Garcia, V. M., Fernandez-Recio, J., Allende, J. E. and Blundell, T. L. (2006) Identifying interaction motifs in CK2beta-a ubiquitous kinase regulatory subunit. Trends Biochem. Sci. 31, 654-661.
40. Faust, M. and Montenarh, M. (2000) Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res. 301, 329-340.
41. Gyenis, L. and Litchfield, D. W. (2008) The emerging CK2 interactome: insights into the regulation and functions of CK2. Mol. Cell. Biochem. 316, 5-14.
42. Glover, C. V. (1986)Afilamentous form of Drosophila casein kinase II. J. Biol. Chem. 261, 14349-14354.
43. Niefind, K. and Issinger, O. G. (2005) Primary and secondary interactions between CK2alpha and CK2beta lead to ring-like structures in the crystals of the CK2 holoenzyme. Mol. Cell. Biochem. 274, 3-14.
44. Pagano, M. A., Sarno, S., Poletto, G., Cozza, G., Pinna, L. A. and Meggio, F. (2005) Autophosphorylation at the regulatory beta subunit reflects the supramolecular organization of protein kinase CK2. Mol. Cell. Biochem. 274, 23-29.
45. Poole, A., Poore, T., Bandhakavi, S., McCann, R. O., Hanna, D. E. and Glover, C. V. (2005)A global view of CK2 function and regulation. Mol. Cell. Biochem. 274, 163-170.
46. Valero, E., De Bonis, S., Filhol, O., Wade, R. H., Langowski, J., Chambaz, E. M. and Cochet, C. (1995) Quaternary structure of casein kinase 2. Characterization of multiple oligomeric states and relation with its catalytic activity. J. Biol. Chem. 270, 8345-8352.
47. Padmanabha, R., Chen-Wu, J. L., Hanna, D. E. and Glover, C. V. (1990) Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol. Cell. Biol. 10, 4089-4099.
48. Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M. and Ahringer, J. (2000) Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408, 325-330.
49. Buchou, T., Vernet, M., Blond, O., Jensen, H. H., Pointu, H., Olsen, B. B., Cochet, C., Issinger, O. G. and Boldyreff, B. (2003) Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol. Cell. Biol. 23, 908-915.
50. Homma, M. K. and Homma, Y. (2008) Cell cycle and activation of CK2. Mol. Cell. Biochem. 316, 49-55.
51. Ahmad, K. A., Wang, G., Slaton, J., Unger, G. and Ahmed, K. (2005) Targeting CK2 for cancer therapy. Anticancer Drugs 16, 1037-1043.
52. Ahmad, K. A., Wang, G., Unger, G., Slaton, J. and Ahmed, K. (2008) Protein kinase CK2-a key suppressor of apoptosis. Adv. Enzyme Regul. 48, 179-187.
53. Ahmed, K. (2008) Special issue on protein kinase CK2 in health and disease. Preface. Mol. Cell. Biochem. 316, 1-3.
54. Ahmed, K., Gerber, D. A. and Cochet, C. (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 12, 226-230.
55. Sarno, S. and Pinna, L. A. (2008) Protein kinase CK2 as a druggable target. Mol. Biosyst. 4, 889-894.
56. Tawfic, S., Yu, S., Wang, H., Faust, R., Davis, A. and Ahmed, K. (2001) Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 16, 573-582.
57. Channavajhala, P. and Seldin, D. C. (2002) Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 21, 5280-5288.
58. Piazza, F. A., Ruzzene, M., Gurrieri, C., Montini, B., Bonanni, L., Chioetto, G., Di Maira, G., Barbon, F., Cabrelle, A., Zambello, R. et al. (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108, 1698-1707.
59. Ruzzene, M., Penzo, D. and Pinna, L. A. (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem. J. 364, 41-47.
60. Unger, G. M., Davis, A. T., Slaton, J. W. and Ahmed, K. (2004) Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr. Cancer Drug Targets 4, 77-84.
61. Di Maira, G., Salvi, M., Arrigoni, G., Marin, O., Sarno, S., Brustolon, F., Pinna, L. A. and Ruzzene, M. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 12, 668-677.
62. Loizou, J. I., El-Khamisy, S. F., Zlatanou, A., Moore, D. J., Chan, D. W., Qin, J., Sarno, S., Meggio, F., Pinna, L. A. and Caldecott, K. W. (2004) The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell 117, 17-28.
63. Sarno, S., Ruzzene, M., Frascella, P., Pagano, M. A., Meggio, F., Zambon, A., Mazzorana, M., Di Maira, G., Lucchini, V. and Pinna, L. A. (2005) Development and exploitation of CK2 inhibitors. Mol. Cell. Biochem. 274, 69-76.
64. Sarno, S., Salvi, M., Battistutta, R., Zanotti, G. and Pinna, L. A. (2005) Features and potentials of ATP-site directed CK2 inhibitors. Biochim. Biophys. Acta 1754, 263-270.
65. Scaglioni, P. P., Yung, T. M., Cai, L. F., Erdjument-Bromage, H., Kaufman, A. J., Singh, B., Teruya-Feldstein, J., Tempst, P. and Pandolfi, P. P. (2006) A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126, 269-283.
66. Wang, G., Unger, G., Ahmad, K. A., Slaton, J. W. and Ahmed, K. (2005) Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol. Cell. Biochem. 274, 77-84.
67. Slaton, J. W., Unger, G. M., Sloper, D. T., Davis, A. T. and Ahmed, K. (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol. Cancer Res. 2, 712-721.
68. Di Maira, G., Brustolon, F., Bertacchini, J., Tosoni, K., Marmiroli, S., Pinna, L. A. and Ruzzene, M. (2007) Pharmacological inhibition of protein kinase CK2 reverts the multi-drug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26, 6915-6926.
69. Young, T. A., Delagoutte, B., Endrizzi, J. A., Falick, A. M. and Alber, T. (2003) Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Nat. Struct. Biol. 10, 168-174.
70. Hanks, S. K. and Hunter, T. (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596.
71. Traxler, P. and Furet, P. (1999) Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82, 195-206.
72. Traxler, P., Green, J., Mett, H., Sequin, U. and Furet, P. (1999) Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J. Med. Chem. 42, 1018-1026.
73. Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J. and Pavletich, N. P. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313-320.
74. Sarno, S., Vaglio, P., Meggio, F., Issinger, O. G. and Pinna, L. A. (1996) Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. J. Biol. Chem. 271, 10595-10601.
75. Niefind, K., Guerra, B., Pinna, L. A., Issinger, O. G. and Schomburg, D. (1998) Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 A resolution. EMBO J. 17, 2451-2462.
76. Engh, R. A. and Bossemeyer, D. (2002) Structural aspects of protein kinase control-role of conformational flexibility. Pharmacol. Ther. 93, 99-111.
77. Niefind, K., Guerra, B., Ermakowa, I. and Issinger, O. G. (2001) Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 20, 5320-5331.
78. Duncan, J. S. and Litchfield, D. W. (2008) Toomuch of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim. Biophys. Acta 1784, 33-47.
79. Blencke, S., Zech, B., Engkvist, O., Greff, Z., Orfi, L., Horvath, Z., Keri, G., Ullrich, A. and Daub, H. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691-701.
80. Meggio, F., Donella Deana, A., Ruzzene, M., Brunati, A. M., Cesaro, L., Guerra, B., Meyer, T., Mett, H., Fabbro, D., Furet, P., Dobrowolska, G. and Pinna, L. A. (1995) Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 234, 317-322.
81. Bortolato, A., Cozza, G. and Moro, S. (2008) Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents? Anticancer Agents Med. Chem. 8, 798-806.
82. Mazzorana, M., Pinna, L. A. and Battistutta, R. (2008) A structural insight into CK2 inhibition. Mol. Cell. Biochem. 316, 57-62.
83. Pinna, L. A. and Cohen, P. T. W. (2005) Inhibitors of protein kinase CK2: structural aspects. In: Handbook of Experimental Pharmacology, pp. 125-155, Pinna, L. A. and Cohen, P. T. W. (eds.), Springer, Berlin.
84. Ermakova, I., Boldyreff, B., Issinger, O. G. and Niefind, K. (2003) Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. J. Mol. Biol. 330, 925-934.
85. Niefind, K., Yde, C. W., Ermakova, I. and Issinger, O. G. (2007) Evolved to be active: sulfate ions define substrate recognition sites of CK2alpha and emphasise its exceptional role within the CMGC family of eukaryotic protein kinases. J. Mol. Biol. 370, 427-438.
86. Battistutta, R., Sarno, S., De Moliner, E., Papinutto, E., Zanotti, G. and Pinna, L. A. (2000) The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 275, 29618-29622.
87. Raaf, J., Klopffleisch, K., Issinger, O. G. and Niefind, K. (2008) The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin. J. Mol. Biol. 377, 1-8.
88. Yim, H., Lee, Y. H., Lee, C. H. and Lee, S. K. (1999) Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med. 65, 9-13.
89. Sarno, S., Moro, S., Meggio, F., Zagotto, G., Dal Ben, D., Ghisellini, P., Battistutta, R., Zanotti, G. and Pinna, L. A. (2002) Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol. Ther. 93, 159-168.
90. Scapin, G. (2002) Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 7, 601-611.
91. De Moliner, E., Moro, S., Sarno, S., Zagotto, G., Zanotti, G., Pinna, L. A. and Battistutta, R. (2003) Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J. Biol. Chem. 278, 1831-1836.
92. Salvi, M., Sarno, S., Marin, O., Meggio, F., Itarte, E. and Pinna, L. A. (2006) Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits. FEBS Lett. 580, 3948-3952.
93. Pagano, M. A., Bain, J., Kazimierczuk, Z., Sarno, S., Ruzzene, M., Di Maira, G., Elliott, M., Orzeszko, A., Cozza, G., Meggio, F. and Pinna, L. A. (2008)The selectivity of inhibitors of protein kinase CK2: An update. Biochem. J. 415, 353-365.
94. Vangrevelinghe, E., Zimmermann, K., Schoepfer, J., Portmann, R., Fabbro, D. and Furet, P. (2003) Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 46, 2656-2662.
95. Sarno, S., de Moliner, E., Ruzzene, M., Pagano, M. A., Battistutta, R., Bain, J., Fabbro, D., Schoepfer, J., Elliott, M., Furet, P., Meggio, F., Zanotti, G. and Pinna, L. A. (2003) Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6- dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA) Biochem. J. 374, 639-646.
96. Duncan, J. S., Gyenis, L., Lenehan, J., Bretner, M., Graves, L. M., Haystead, T. A. and Litchfield, D. W. (2008) An unbiased evaluation of CK2 inhibitors by chemoproteomics: Characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol. Cell. Proteomics 7, 1077-1088.
97. Zandomeni, R., Zandomeni, M. C., Shugar, D. and Weinmann, R. (1986) Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D- ribofuranosylbenzimidazole of specific RNA polymerase II transcription. J. Biol. Chem. 261, 3414-3419.
98. Shugar, D. (1999) Viral and host-cell protein kinases: enticing antiviral targets and relevance of nucleoside, and viral thymidine, kinases. Pharmacol. Ther. 82, 315-335.
99. Szyszka, R., Grankowski, N., Felczak, K. and Shugar, D. (1995) Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. Biochem. Biophys. Res. Commun. 208, 418-424.
100. Sarno, S., Reddy, H., Meggio, F., Ruzzene, M., Davies, S. P., Donella-Deana, A., Shugar, D. and Pinna, L. A. (2001) Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2') FEBS Lett. 496, 44-48.
101. Battistutta, R., De Moliner, E., Sarno, S., Zanotti, G. and Pinna, L. A. (2001) Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci. 10, 2200-2206.
102. Zien, P., Duncan, J. S., Skierski, J., Bretner, M., Litchfield, D. W. and Shugar, D. (2005) Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: Evaluation of their effects on cells and different molecular forms of human CK2. Biochim. Biophys. Acta 1754, 271-280.
103. Battistutta, R., Mazzorana, M., Cendron, L., Bortolato, A., Sarno, S., Kazimierczuk, Z., Zanotti, G., Moro, S. and Pinna, L. A. (2007) The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. Chembiochem 8, 1804-1809.
104. Auffinger, P., Hays, F. A., Westhof, E. and Ho, P. S. (2004) Halogen bonds in biological molecules. Proc. Natl. Acad. Sci. USA 101, 16789-16794.
105. Politzer, P., Lane, P., Concha, M. C., Ma, Y. and Murray, J. S. (2007) An overview of halogen bonding. J. Mol. Model. 13, 305-311.
106. Golub, A. G., Yakovenko, O. Y., Prykhod'ko, A. O., Lukashov, S. S., Bdzhola, V. G. and Yarmoluk, S. M. (2008) Evaluation of 4,5,6,7-tetrahalogeno- 1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2. Biochim. Biophys. Acta 1784, 143-149.
107. Battistutta, R., Mazzorana, M., Sarno, S., Kazimierczuk, Z., Zanotti, G. and Pinna, L. A. (2005) Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. Chem. Biol. 12, 1211-1219.
108. Bortolato, A. and Moro, S. (2007) In silico binding free energy predictability by using Linear Interaction Energy (LIE) method: Bromo-benzimidazole CK2 inhibitors as case study. J. Chem. Inf. Model. 47, 572-582.
109. Pagano, M. A., Poletto, G., Di Maira, G., Cozza, G., Ruzzene, M., Sarno, S., Bain, J., Elliott, M., Moro, S., Zagotto, G. et al. (2007) Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 8, 129-139.
110. Kazimierczuk, Z., Stolarski, R. and Shugar, D. (1985) Stereo-specific synthesis by the sodium salt glycosylation method of halogeno benzimidazole 2′-deoxyribose analogues of the inhibitor of hnRNA synthesis, 5,6-dichloro-1-(beta-D-ribofuranosyl) benzimidazole (DRB) Z. Naturforsch. [C] 40, 715-720.
111. Meggio, F., Shugar, D. and Pinna, L. A. (1990) Ribofuranosyl- benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur. J. Biochem. 187, 89-94.
112. Raaf, J., Brunstein, E., Issinger, O. G. and Niefind, K. (2008) The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem. Biol. 15, 111-117.
113. Raaf, J., Issinger, O. G. and Niefind, K. (2008) Insights from soft X-rays: The chlorine and sulfur sub-structures of a CK2alpha/DRB complex. Mol. Cell. Biochem. 316, 15-23.
114. Chilin, A., Battistutta, R., Bortolato, A., Cozza, G., Zanatta, S., Poletto, G., Mazzorana, M., Zagotto, G., Uriarte, E., Guiotto, A. et al. (2008) Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: An integrated approach to elucidate the putative binding motif and explain structure-activity relationships. J. Med. Chem. 51, 752-759.
115. Cozza, G., Bonvini, P., Zorzi, E., Poletto, G., Pagano, M. A., Sarno, S., Donella-Deana, A., Zagotto, G., Rosolen, A., Pinna, L. A. et al. (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application. J. Med. Chem. 49, 2363-2366.
116. Nie, Z., Perretta, C., Erickson, P., Margosiak, S., Almassy, R., Lu, J., Averill, A., Yager, K. M. and Chu, S. (2007) Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2. Bioorg. Med. Chem. Lett. 17, 4191-4195.
117. Nie, Z., Perretta, C., Erickson, P., Margosiak, S., Lu, J., Averill, A., Almassy, R. and Chu, S. (2008) Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg. Med. Chem. Lett. 18, 619-623.
118. De Moliner, E., Brown, N. R. and Johnson, L. N. (2003) Alternative binding modes of an inhibitor to two different kinases. Eur. J. Biochem. 270, 3174-3181.
119. Marin, O., Meggio, F., Boldyreff, B., Issinger, O. G. and Pinna, L. A. (1995) Dissection of the dual function of the beta-subunit of protein kinase CK2 ('casein kinase-2'): Asynthetic peptide reproducing the carboxyl-terminal domain mimicks the positive but not the negative effects of the whole protein. FEBS Lett. 363, 111-114.
120. Marin, O., Meggio, F., Sarno, S. and Pinna, L. A. (1997) Physical dissection of the structural elements responsible for regulatory properties and intersubunit interactions of protein kinase CK2 beta-subunit. Biochemistry 36, 7192-7198.
121. Battistutta, R., Sarno, S., De Moliner, E., Marin, O., Issinger, O. G., Zanotti, G. and Pinna, L. A. (2000) The crystal structure of the complex of Zea mays alpha subunit with a fragment of human beta subunit provides the clue to the architecture of protein kinase CK2 holoenzyme. Eur. J. Biochem. 267, 5184-5190.
122. Laudet, B., Barette, C., Dulery, V., Renaudet, O., Dumy, P., Metz, A., Prudent, R., Deshiere, A., Dideberg, O., Filhol, O. and Cochet, C. (2007) Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem. J. 408, 363-373.
123. Pagano, M. A., Arrigoni, G., Marin, O., Sarno, S., Meggio, F., Treharne, K. J., Mehta, A. and Pinna, L. A. (2008) Modulation of protein kinase CK2 activity by fragments of CFTR encompassing F508 may reflect functional links with cystic fibrosis pathogenesis. Biochemistry 47, 7925-7936.
124. Laudet, B., Moucadel, V., Prudent, R., Filhol, O., Wong, Y. S., Royer, D. and Cochet, C. (2008) Identification of chemical inhibitors of protein-kinase CK2 subunit interaction. Mol. Cell. Biochem. 316, 63-69.
125. Prudent, R., Moucadel, V., Laudet, B., Barette, C., Lafanechere, L., Hasenknopf, B., Li, J., Bareyt, S., Lacote, E., Thorimbert, S. et al. (2008) Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem. Biol. 15, 683-692.
126. Perea, S. E., Reyes, O., Baladron, I., Perera, Y., Farina, H., Gil, J., Rodriguez, A., Bacardi, D., Marcelo, J. L., Cosme, K. et al. (2008) CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol. Cell. Biochem. 316, 163-167.
127. Perea, S. E., Reyes, O., Puchades, Y., Mendoza, O., Vispo, N. S., Torrens, I., Santos, A., Silva, R., Acevedo, B., Lopez, E. (2004) Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 64, 7127-7129.
128. Perera, Y., Farina, H. G., Hernandez, I., Mendoza, O., Serrano, J. M., Reyes, O., Gomez, D. E., Gomez, R. E., Acevedo, B. E., Alonso, D. F. et al. (2008) Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int. J. Cancer 122, 57-62.
129. Frye, S. V. (1999) Structure-activity relationship homology (SARAH):Aconceptual framework for drug discovery in the genomic era. Chem. Biol. 6, R3-7.